References
- Antoniou T, Tseng AL. (2005). Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44:111–45
- AstraZeneca. (2014). Lynparza™ approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/20141218-lynparza-approved-in-the-european-union
- Berretta M, Caraglia M, Martellotta F, et al. (2016). Drug–drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection. Front Pharmacol 7:71
- Binkhorst L, van Gelder T, Loos WJ, et al. (2012). Effects of CYP induction by rifampicin on tamoxifen exposure. Clin Pharmacol Ther 92:62–7
- Cederbaum AI. (2015). Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications. Redox Biol 4:60–73
- Desta Z, Ward BA, Soukhova NV, Flockhart DA. (2004). Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–75
- Dirix L, Swaisland H, Verheul HMW, et al. (2016). Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. Clin Ther 38:2286–99
- Electronic Medicines Compendium. (2017). Summary Product Characteristics: letrozole 2.5 mg film-coated tablets. Available at: http://www.medicines.org.uk/emc/medicine/31659
- European Medicines Agency. (2013). Guideline on the investigation of drug interactions. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/08/WC500147164.pdf
- Evers B, Drost R, Schut E, et al. (2008). Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 14:3916–25
- FDA. (2012). Guidance for industry. Drug interaction studies – study design, data analysis, and implications for dosing and labeling recommendations. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
- FDA. (2014). Olaparib press release. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427598.htm
- Galetin A, Clarke SE, Houston JB. (2002). Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30:1512–22
- Kamdem LK, Liu Y, Stearns V, et al. (2010). In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 70:854–69
- Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. (2015). Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation. J Clin Oncol 33:244–50
- Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. (1999). CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716–27
- Ledermann J, Harter P, Gourley C, et al. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852–61
- McCormick A, Swaisland H. (2016). In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib. Xenobiotica 1:47
- Morgan ET. (2009). Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434–8
- Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 35:246–55
- Ogu CC, Maxa JL. (2000). Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent) 13:421–3
- Pelkonen O, Turpeinen M, Hakkola J, et al. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667–715
- Plummer R, Verheul HMW, Langenberg MHG, et al. (2016). Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole, or letrozole: phase I study. J Clin Oncol (Meeting Abstracts) 34:2562
- Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. (2010). Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49:1603–16
- Rottenberg S, Jaspers JE, Kersbergen A, et al. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079–84
- Rowland M, Tozer TN. (2010). Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Lippincott: Williams & Wilkins
- Sinz M, Wallace G, Sahi J. (2008). Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10:391–400
- Tutt A, Robson M, Garber JE, et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–44
- Wirz B, Valles B, Parkinson A, et al. (1996). CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole. ISSX Proc 10:359
- Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41